SPDEF and prostate carcinoma: By analyzing the expression profiles of RNA biomarkers such as ERG, PCA3, and SPDEF in exosomes, this technology can effectively distinguish high-risk prostate cancer (Gleason score ≥ 7) from low-risk cases.